AMAG Pharmaceuticals (NASDAQ:AMAG) had its hold rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $17.00 price target on the stock. The analysts wrote, “Makena auto-injector is approved. AMAG announced today that the Makena auto-injector was approved. Although the PK data revealed a deficiency in the C max and AMAG disclosed that the FDA commented it would likely create a review issue, we suspect most investors believed the approval would occur.””
Domino's Pizza (NYSE:DPZ) had its price target boosted by Oppenheimer Holdings Inc. from $220.00 to $230.00. The firm currently has an outperform rating on the stock.
FMC (NYSE:FMC) had its positive rating reaffirmed by analysts at Loop Capital. They currently have a $111.00 price target on the stock, up from their previous price target of $108.00.
Healthcare Realty Trust (NYSE:HR) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. They currently have a $38.00 target price on the stock. The analysts wrote, “HR reported in-line 4Q17 results and expects more capital recycling in 2018. The company also started a major development in Seattle. 4Q17 revenue was $107.7 million vs. our $111.4 million estimate, and 4Q17 normalized FFO was $0.38 vs. our $0.39 estimate.””
HubSpot (NYSE:HUBS) had its price target boosted by SunTrust Banks, Inc. to $112.00. The firm currently has a buy rating on the stock.
HubSpot (NYSE:HUBS) had its price target increased by Canaccord Genuity from $98.00 to $115.00. Canaccord Genuity currently has a buy rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its target price increased by Deutsche Bank AG to $97.00. Deutsche Bank AG currently has a buy rating on the stock.
Rio Tinto (NYSE:RIO) had its target price boosted by Argus to $61.00. The firm currently has a buy rating on the stock.
S&P Global (NYSE:SPGI) had its target price raised by Argus to $210.00. The firm currently has a buy rating on the stock.
Tripadvisor (NASDAQ:TRIP) had its hold rating reissued by analysts at Wells Fargo & Co. The analysts wrote, “We note that Street consensus for 2018 EBITDA had stood at $303MM prior to the print, implying an 8% yr/yr decline vs. reported 2017 EBITDA of $331MM. TripAdvisor, Inc. (TRIP)/Market Perform (2) Price as of 2/14/2018: $40.72 FY 17 CASH EPS: $1.11 FY 18 CASH EPS: $1.02 Shares Out.: 139.0 MM Market Cap.: $5,660.08 MM Rating Basis Information: TRIP Thesis: Though we favor Tripadvisor’s strong consumer brand position and global reach, we believe pivot of brand positioning toward price comparison could yield a new level of competitive pressure and we remain concerned that sacrificing performance marketing for brand TV could have a nearterm negative impact on fundamentals. This concern and what we believe to be a full valuation lead us to maintain our Market Perform rating.””
Receive News & Ratings for AMAG Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.